Skip to Main Content

Christopher van Dyck, MD

Professor of Psychiatry, Neurology, and Neuroscience; Director, Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry

Contact Information

Christopher van Dyck, MD

Mailing Address

  • Yale School of Medicine

    One Church Street

    New Haven, CT 06510

    United States

Research Summary

Christopher H. van Dyck, MD, is Professor of Psychiatry, Neurology, and Neuroscience; Director of the Alzheimer's Disease Research Unit; Director, Yale Alzheimer's Disease Research Center; Director, Division of Aging and Geriatric Psychiatry.

His research focuses on neuroimaging and therapeutic studies of Alzheimer’s disease (AD) and brain aging. His current imaging research utilizes positron emission tomography (PET) to study the beta-amyloid (Aβ) and tau proteins, as well as the synaptic targets SV2A and mGluR5. He and his team are examining the full spectrum of AD, including AD-dementia, the prodromal condition of amnestic Mild Cognitive Impairment (aMCI), and preclinical AD—in individuals at high familial and genetic risk.

He also has extensive experience in the conduct and leadership of therapeutic trials in AD. Since 1991 he has led or participated in approximately 90 clinical trials for AD, including the prodromal or preclinical stages. He currently serves on the Steering and Executive Committees and Co-Chairs the Protocol Evaluation Committee of the Alzheimer’s Clinical Trials Consortium (ACTC). He also serves on the Steering Committees of the Alzheimer's Disease Cooperative Study (ADCS), the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the Alzheimer's Therapeutic Research Institute (ATRI). His research accomplishments have been recognized by receipt of the 1996 Junior Investigator Award of the American Association of Geriatric Psychiatry, the 2005 Compassion and Cure Award of the Alzheimer’s Association, and the 2017 Leader in Advancing Research Award of the Alzheimer’s Association. He has published more than 200 peer-reviewed papers, more than 100 of which pertain to Alzheimer's disease.

Specialized Terms: Alzheimer's disease; Brain aging; Cognitive aging; Pharmacotherapy; Neuroimaging; Genetics

Extensive Research Description

Dopamine Transporter (DAT) Imaging in Aging.

He has used SPECT imaging to demonstrate a 50% loss of DATs over the lifespan and has further shown that this loss of dopamine is associated with the slowing of reaction time that is characteristic of the normal aging process.


The Apolipoprotein E e4 (ApoE e4) Phenotype of AD.
He has combined genetics and neuroimaging to characterize the role of the most common genetic risk factor, ApoE e4, in structural and cognitive changes in AD. He has found that patients who carry the ApoE e4 allele are at greater risk for psychosis and for loss of medial temporal lobe tissue. He is now using the PET ligand [11C]PIB to assess amyloid plaques in asymptomatic first-degree relatives as a function of ApoE e4 genotype.

  • Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects (funded by NIA). The major goal of this project is to test the hypothesis that low doses of the alpha-2A-adrenoceptor agonist guanfacine can improve deficits in prefrontally-mediated working memory and executive control functions in healthy elderly subjects.
  • Amyloid Binding In Subjects At Risk For Alzheimer’s Disease (funded by Alzheimer's Association). The major goal of this project is to test the hypothesis that in vivo brain Aß burden as measured using [11C]PIB and PET is increased in healthy subjects with a family history of AD who are homozygous or heterozygous for the ApoE e4 allele compared to subjects who lack this allele.
  • Alzheimer’s Disease Cooperative Study Unit (ADCS, funded by NIA). The major goal of this multicenter consortium is to conduct clinical trial research in Alzheimer’s disease that would not otherwise be conducted by private pharmaceutical corporations. Role: Principal Investigator for Yale Site (PI: Paul Aisen, University of California, San Diego)
  • Alzheimer’s Disease Neuroimaging Initiative (ADNI, funded by NIA) The major goals of this project are to: 1. Develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on patients with Alzheimer’s disease, mild cognitive impairment, and elderly controls. 2. Acquire a generally accessible data repository, which describes longitudinal changes in brain structure and metabolism. In parallel, acquire clinical cognitive and biomarker data for validation of imaging surrogates. Role: Principal Investigator for Yale Site (PI: University of California, San Francisco)

Coauthors

Research Interests

Aging; Alzheimer Disease; Drug Therapy; Genetics; Neurobiology; Neurology; Psychiatry; Positron-Emission Tomography; Neuroimaging

Research Image

Selected Publications

  • Investigating Partially Discordant Results in Phase 3 Studies of AducanumabMallinckrodt C, Tian Y, Aisen P, Barkhof F, Cohen S, Dent G, Hansson O, Harrison K, Iwatsubo T, Mummery C, Muralidharan K, Nestorov I, Nisenbaum L, Rajagovindan R, von Hehn C, van Dyck C, Vellas B, Wu S, Zhu Y, Sandrock A, Chen T, Budd Haeberlein S. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab The Journal Of Prevention Of Alzheimer's Disease 2023, 1-7. DOI: 10.14283/jpad.2023.6.
  • P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s DiseaseKelly K, Kelly K, O'Dell R, Toyonaga T, Barcelos N, Barcelos N, Gelernter J, Varma P, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s Disease Biological Psychiatry 2022, 91: s125-s126. DOI: 10.1016/j.biopsych.2022.02.329.
  • The relationship between cortical amyloid burden and basal forebrain volume in adults at varying APOE ?4 risk for Alzheimer's diseaseKelly K, Kelly K, Toyonaga T, Zhao W, Barcelos N, Barcelos N, Gelernter J, Varma P, Nabulsi N, Wyk B, Wyk B, Huang Y, Carson R, van Dyck C, Mecca A. The relationship between cortical amyloid burden and basal forebrain volume in adults at varying APOE ?4 risk for Alzheimer's disease American Journal Of Geriatric Psychiatry 2022, 30: s25. DOI: 10.1016/j.jagp.2022.01.301.
  • Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PETSilva-Rudberg J, Silva-Rudberg J, Salardini E, Salardini E, O'Dell R, Chen M, Ra J, Ra J, Georgelos J, Georgelos J, Morehouse M, Morehouse M, Melino K, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PET American Journal Of Geriatric Psychiatry 2022, 30: s26. DOI: 10.1016/j.jagp.2022.01.303.
  • All that's Amnestic Isn't Alzheimer's: a Clinical Case Report of an Alzheimer's disease-like Amnestic Syndrome with Incongruent BiomarkersO'Dell R, van Dyck C, Mecca A. All that's Amnestic Isn't Alzheimer's: a Clinical Case Report of an Alzheimer's disease-like Amnestic Syndrome with Incongruent Biomarkers American Journal Of Geriatric Psychiatry 2022, 30: s24. DOI: 10.1016/j.jagp.2022.01.295.
  • Subcellular localization of PDE4D and HCN1 in rhesus macaque entorhinal cortex layer II: Signature of vulnerability in Alzheimer’s diseaseDatta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. Subcellular localization of PDE4D and HCN1 in rhesus macaque entorhinal cortex layer II: Signature of vulnerability in Alzheimer’s disease Alzheimer's & Dementia 2022, 17 DOI: 10.1002/alz.054671.
  • Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s diseaseMecca A, Ashton N, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Zhao W, Nabulsi N, Brinkmalm A, Brinkmalm A, Kvartsberg H, Kvartsberg H, Schöll M, Schöll M, Arnsten A, Huang Y, Blennow K, Blennow K, Zetterberg H, Zetterberg H, Carson R, van Dyck C, Nilsson J, Nilsson J. Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s disease Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054831.
  • Apathy in Dementia Methylphenidate Trial 2 (ADMET2): Results of a phase III, placebo‐controlled, double‐blind, 6‐month, multi‐center, randomized clinical trialMintzer J, Scherer R, Drye L, Lanctôt K, Rosenberg P, Herrmann N, Padala P, Brawman‐Mintzer O, Lerner A, Levey A, Porsteinsson A, van Dyck C. Apathy in Dementia Methylphenidate Trial 2 (ADMET2): Results of a phase III, placebo‐controlled, double‐blind, 6‐month, multi‐center, randomized clinical trial Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.051489.
  • [11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid‐β clearanceChen C, McCullough A, Gordon B, Joseph‐Mathurin N, Wang G, Li Y, Xiong C, Pontecorvo M, Klein G, Shcherbinin S, Higgins I, Masters C, Clifford D, van Dyck C, Masellis M, Hsiung G, Gauthier S, Bateman R, McDade E, Salloway S, Benzinger T. [11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid‐β clearance Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.056094.
  • EXERT: Impact of COVID‐19 on retention and intervention delivery of a large multisite exercise trial in adults with MCIBaker L, Cotman C, Morrison R, Katula J, Chmelo E, Hodge H, Johnson C, Kipperman S, Matthews G, Bennett D, Mason J, LaCroix A, van Dyck C, Okonkwo O, Tam S, Fairchild J, Li C, Welsh‐Bohmer K, Feldman H, Group T. EXERT: Impact of COVID‐19 on retention and intervention delivery of a large multisite exercise trial in adults with MCI Alzheimer's & Dementia 2021, 17: e056518. PMCID: PMC9011773, DOI: 10.1002/alz.056518.
  • Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐Jvan Dyck C, Sharp E, O'Dell R, Banks E, Banks E, Bartlett H, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Harris J, Ni G, Ni G, Zhao W, Nabulsi N, Wyk B, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A. Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐J Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054213.
  • Synthesizing Multi-tracer PET Images for Alzheimer’s Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial NetworkZhou B, Wang R, Chen M, Mecca A, O’Dell R, Van Dyck C, Carson R, Duncan J, Liu C. Synthesizing Multi-tracer PET Images for Alzheimer’s Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial Network 2021, 12906: 34-43. DOI: 10.1007/978-3-030-87231-1_4.
  • Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-JO'Dell R, Mecca A, Sharp E, Banks E, Banks E, Bartlett H, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Harris J, Ni G, Ni G, Zhao W, Nabulsi N, Wyk B, Wyk B, Huang Y, Carson R, Arnsten A, van Dyck C. Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-J Biological Psychiatry 2021, 89: s107-s108. DOI: 10.1016/j.biopsych.2021.02.276.
  • Association of Aß deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-JO'Dell R, Mecca A, Chen M, Naganawa M, Toyonaga T, Lu Y, Lu Y, Godek T, Godek T, Harris J, Harris J, Bartlett H, Bartlett H, Banks E, Banks E, Kominek V, Kominek V, Zhao W, Nabulsi N, Ropchan J, Ye Y, Wyk B, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C. Association of Aß deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J American Journal Of Geriatric Psychiatry 2021, 29: s37-s40. DOI: 10.1016/j.jagp.2021.01.034.
  • Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-JSharp E, O'Dell R, Banks E, Banks E, Bartlett H, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Ni G, Zhao W, Nabulsi N, Wyk B, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A, van Dyck C. Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-J American Journal Of Geriatric Psychiatry 2021, 29: s119-s120. DOI: 10.1016/j.jagp.2021.01.114.
  • Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's diseaseO'Dell R, Higgins-Chen A, Gupta D, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Lu Y, Banks E, Banks E, Bartlett H, Bartlett H, Harris J, Harris J, Zhao W, Nabulsi N, Wyk B, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease American Journal Of Geriatric Psychiatry 2021, 29: s47-s48. DOI: 10.1016/j.jagp.2021.01.041.
  • Age-Related Brain Structure Differences, by Age of Onset, in Older Adults with Bipolar DisorderVilla L, Colic L, Sankar A, Goldman D, Lessing B, Alexopoulos G, van Dyck C, Blumberg H. Age-Related Brain Structure Differences, by Age of Onset, in Older Adults with Bipolar Disorder American Journal Of Geriatric Psychiatry 2021, 29: s26. DOI: 10.1016/j.jagp.2021.01.019.
  • PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s diseaseSalardini A, Salardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Hashemi‐Aghdam A, Laltoo E, Laltoo E, Savoia S, Savoia S, O'Dell R, Harris J, Harris J, Godek T, Godek T, Nabulsi N, Lim K, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037792.
  • Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s diseaseMecca A, Ashton N, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Harris J, Harris J, Bartlett H, Bartlett H, Banks E, Banks E, Kominek V, Kominek V, Nabulsi N, Najafzadeh S, Wyk B, Wyk B, Brinkmalm A, Brinkmalm A, Kvartsberg H, Kvartsberg H, Schöll M, Schöll M, Arnsten A, Huang Y, Blennow K, Blennow K, Zetterberg H, Zetterberg H, Carson R, van Dyck C. Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.044211.
  • 11C‐PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s diseaseSalardini A, Salardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Hashemi‐Aghdam A, Laltoo E, Laltoo E, Savoia S, Savoia S, O'Dell R, Harris J, Harris J, Godek T, Godek T, Nabulsi N, Lim K, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. 11C‐PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043584.
  • Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET studyO'Dell R, Mecca A, Chen M, Godek T, Godek T, Harris J, Harris J, Bartlett H, Bartlett H, Banks E, Banks E, Kominek V, Zhao W, Naganawa M, Toyonaga T, Lu Y, Lu Y, Nabulsi N, Ropchan J, Ye Y, Wyk B, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET study Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043631.
  • ICA‐derived sources of synaptic density PET ([11C]UCB‐J) relate to cognitive impairment severity in Alzheimer’s diseaseFang X, Mecca A, Naganawa M, O'Dell R, Chen M, van Dyck C, Carson R. ICA‐derived sources of synaptic density PET ([11C]UCB‐J) relate to cognitive impairment severity in Alzheimer’s disease Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.041197.
  • In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s diseaseMecca A, O'Dell R, Chen M, Naganawa M, Toyonaga T, Godek T, Godek T, Harris J, Harris J, Bartlett H, Bartlett H, Zhao W, Gallezot J, Nabulsi N, Ropchan J, Ye Y, Wyk B, Wyk B, Arnsten A, Huang Y, Carson R, van Dyck C. In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s disease Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037791.
  • Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer’s disease using [11C]UCB‐J PETO'Dell R, Naganawa M, Toyonaga T, Young J, Dahal R, Singh E, Singh E, Waheed A, Waheed A, Banks E, Banks E, Harris J, Harris J, Chen M, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer’s disease using [11C]UCB‐J PET Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.045928.
  • Recruitment for a multi‐site randomized controlled trial of aerobic exercise for older adults with amnestic mild cognitive impairment: The EXERT trialLaCroix A, van Dyck C, Okonkwo O, Tam S, Fairchild J, Li C, Welsh‐Bohmer K, Shadyab A, Matthews G, Bennett D, Shadyab A, Schafer K, Morrison R, Kipperman S, Tan D, Feldman H, Cotman C, Baker L, Group E. Recruitment for a multi‐site randomized controlled trial of aerobic exercise for older adults with amnestic mild cognitive impairment: The EXERT trial Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.044658.
  • Gantenerumab in‐depth outcomesSalloway S, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Farlow M, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Baudler M, Delmar P, Doody R, Fontoura P, Kerchner G, Team D. Gantenerumab in‐depth outcomes Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038049.
  • The calcium‐containing smooth endoplasmic reticulum is a focus of risk factors for early‐ and late‐onset Alzheimer’s diseaseDatta D, Mentone S, Morozov Y, van Dyck C, Arnsten A. The calcium‐containing smooth endoplasmic reticulum is a focus of risk factors for early‐ and late‐onset Alzheimer’s disease Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.047651.
  • Solanezumab in‐depth outcomesFarlow M, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Salloway S, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Andersen S, Holdridge K, Mintun M, Sims J, Yaari R, Team D. Solanezumab in‐depth outcomes Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038028.
  • Biochemical characterization of age‐related calcium‐cAMP‐PKA signaling dysregulation and its effect on tau pathology in rhesus monkey cortexLeslie S, Datta D, Wang M, van Dyck C, Arnsten A, Nairn A. Biochemical characterization of age‐related calcium‐cAMP‐PKA signaling dysregulation and its effect on tau pathology in rhesus monkey cortex Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.042017.
  • ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDYO'Dell R, Mecca A, Chen M, Godek T, Godek T, Harris J, Harris J, Bartlett H, Bartlett H, Zhao W, Naganawa M, Toyonaga T, Lu Y, Lu Y, Nabulsi N, Wyk B, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY American Journal Of Geriatric Psychiatry 2020, 28: s123-s124. DOI: 10.1016/j.jagp.2020.01.153.
  • F164. Ultrastructural Localization of Classical Complement Cascade Signaling Protein C1q in Rhesus Macaque Dorsolateral Prefrontal CortexDatta D, Morozov Y, van Dyck C, Arnsten A. F164. Ultrastructural Localization of Classical Complement Cascade Signaling Protein C1q in Rhesus Macaque Dorsolateral Prefrontal Cortex Biological Psychiatry 2019, 85: s276-s277. DOI: 10.1016/j.biopsych.2019.03.701.
  • ASSOCIATION BETWEEN ODOR IDENTIFICATION AND REGIONAL GRAY MATTER IN EARLY PRECLINICAL ALZHEIMER'S DISEASEGupta M, O'Dell R, Gelernter J, Carson R, van Dyck C, Mecca A. ASSOCIATION BETWEEN ODOR IDENTIFICATION AND REGIONAL GRAY MATTER IN EARLY PRECLINICAL ALZHEIMER'S DISEASE American Journal Of Geriatric Psychiatry 2019, 27: s143-s144. DOI: 10.1016/j.jagp.2019.01.098.
  • REGION-SPECIFIC ATROPHY AS MEASURED BY CORTICAL GRAY MATTER VOLUME IS ASSOCIATED WITH BOTH REGIONAL AND TOTAL CORTICAL AMYLOID-BETA BURDEN IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASEO'Dell R, Gupta M, Gelernter J, Carson R, van Dyck C, Mecca A. REGION-SPECIFIC ATROPHY AS MEASURED BY CORTICAL GRAY MATTER VOLUME IS ASSOCIATED WITH BOTH REGIONAL AND TOTAL CORTICAL AMYLOID-BETA BURDEN IN COGNITIVELY NORMAL INDIVIDUALS AT RISK FOR ALZHEIMER'S DISEASE American Journal Of Geriatric Psychiatry 2019, 27: s145-s146. DOI: 10.1016/j.jagp.2019.01.100.
  • Poster Number: NR 14 Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials?Mecca A, Chen M, Naganawa M, Finnema S, Finnema S, Toyonaga T, Lin S, Lin S, McDonald J, McDonald J, Michalak H, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Poster Number: NR 14 Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials? American Journal Of Geriatric Psychiatry 2018, 26: s145-s146. DOI: 10.1016/j.jagp.2018.01.176.
  • Poster Number: EI 39 Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PETMecca A, Rogers K, Rogers K, Jacobs Z, Jacobs Z, McDonald J, McDonald J, Michalak H, Michalak H, DellaGioia N, Nabulsi N, Matuskey D, Esterlis I, Carson R, van Dyck C. Poster Number: EI 39 Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PET American Journal Of Geriatric Psychiatry 2017, 25: s96-s97. DOI: 10.1016/j.jagp.2017.01.110.
  • The role of norepinephrine transporter in attention deficit hyperactivity disorderDing Y, Planeta-Wilson B, Hannestad J, Gallezot J, Lin S, Williams W, Quinlan D, Carson R, van Dyck C. The role of norepinephrine transporter in attention deficit hyperactivity disorder NeuroImage 2010, 52: s108. DOI: 10.1016/j.neuroimage.2010.04.087.
  • SPECT imaging of [123I]5-IA-85380 binding to beta2-nicotinic acetylcholine receptors in healthy smokers: Assessment of nondisplaceable uptakeBatis J, Esterlis I, Bois F, Cosgrove K, Stiklus S, Kloczynski T, McKee S, Jatlow P, O'Malley S, Seibyl J, Tamagnan G, Van Dyck C, Staley J. SPECT imaging of [123I]5-IA-85380 binding to beta2-nicotinic acetylcholine receptors in healthy smokers: Assessment of nondisplaceable uptake NeuroImage 2008, 41: t175. DOI: 10.1016/j.neuroimage.2008.04.142.
  • Single nucleotide polymorphisms of ANKK1 and CHRNA4: Influence on nicotinic acetylcholine receptor availability in nonsmokers measured using [123I]5-IA-85380 SPECTBatis J, Yang B, Cosgrove K, Bois F, Esterlis I, Stiklus S, Kloczynski T, Perry E, Seibyl J, Tamagnan G, Van Dyck C, Gelernter J, Staley J. Single nucleotide polymorphisms of ANKK1 and CHRNA4: Influence on nicotinic acetylcholine receptor availability in nonsmokers measured using [123I]5-IA-85380 SPECT NeuroImage 2008, 41: t174. DOI: 10.1016/j.neuroimage.2008.04.141.
  • [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokersStaley J, Tellioglu T, Bois F, Palazzo C, McGuire-Schwartz N, Cosgrove K, van Dyck C, Tamagnan G, Seibyl J, Krystal J, D'Souza D. [I-123] 5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptors in recently abstinent mentally healthy and schizophrenic smokers NeuroImage 2006, 31: t154. DOI: 10.1016/j.neuroimage.2006.04.137.
  • Dr. Kugaya and Colleagues ReplyKUGAYA A, EPPERSON C, van DYCK C, FUJITA M, INNIS R. Dr. Kugaya and Colleagues Reply American Journal Of Psychiatry 2004, 161: 2136-a-2136. DOI: 10.1176/appi.ajp.161.11.2136-a.
  • P4.028 Functional and behavioral effects of memantinein Alzheimer's diseasevan Dyck C, Cummings J, Schmitt F, Graham S, Olin J, Jin J, Tariot P. P4.028 Functional and behavioral effects of memantinein Alzheimer's disease European Neuropsychopharmacology 2004, 14: s334-s335. DOI: 10.1016/s0924-977x(04)80452-8.
  • P1-315 Functional and behavioral effects of memantine in Alzheimer's diseaseCummings J, van Dyck C, Schmitt F, Graham S, Olin J, Jin J, Tariot P. P1-315 Functional and behavioral effects of memantine in Alzheimer's disease Neurobiology Of Aging 2004, 25: s186. DOI: 10.1016/s0197-4580(04)80628-6.
  • P2-393 Alzheimer's disease patient and caregiver attitudes about proxy informed consentKarlawish J, James B, Kim S, Knopman D, van Dyck C, Marson D. P2-393 Alzheimer's disease patient and caregiver attitudes about proxy informed consent Neurobiology Of Aging 2004, 25: s345. DOI: 10.1016/s0197-4580(04)81135-7.
  • Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled TrialMulnard R, Cotman C, Kawas C, van Dyck C, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Study L. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial Obstetrical & Gynecological Survey 2000, 55: 439-440. DOI: 10.1097/00006254-200007000-00021.
  • Apolipoprotein E ε4 allele is associated with atrophy of the amygdala in Alzheimer's diseasevan Dyck C, Basso M, Yang J, Half L, MacAvoy M, Varma P, Gelernter J. Apolipoprotein E ε4 allele is associated with atrophy of the amygdala in Alzheimer's disease Neurobiology Of Aging 2000, 21: 39. DOI: 10.1016/s0197-4580(00)82852-3.
  • 208. Increased striatal dopamine release in drug free schizophrenic subjectsLaruelle M, Abi-Dargham A, van Dyck C, Krystal J, Charney D, Innis R. 208. Increased striatal dopamine release in drug free schizophrenic subjects Biological Psychiatry 1996, 39: 560. DOI: 10.1016/0006-3223(96)84153-9.
  • SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophreniaLaruelle M, Abi-Dargham A, Gil R, van Dyck C, Erdos J, D'Souza D, Rosenblatt W, McCance-Katz E, Zea-Ponce Y, Zoghbi S, Baldwin R, Hoffer P, Krystal J, Charney D, Innis R. SPECT imaging of synaptic dopamine release in drug free schizophrenic patients: An experimental validation of the dopamine hypothesis of schizophrenia Schizophrenia Research 1996, 18: 198-199. DOI: 10.1016/0920-9964(96)85619-2.
  • D-amphetamine displacement of [123I]IBF equilibrium binding in primates: A new paradigm to investigate D-amphetamine induced dopamine release.Laruelle M, Al-Tikriti M, Van Dyck C, Zoghbi S, Zea-Ponce Y, Baldwin R, Charney D, Hoffer P, Innis R. D-amphetamine displacement of [123I]IBF equilibrium binding in primates: A new paradigm to investigate D-amphetamine induced dopamine release. Schizophrenia Research 1993, 9: 201. DOI: 10.1016/0920-9964(93)90423-g.
  • Peptide T Treatment of Cognitive Impairment in HIV‐Positive Intravenous Drug UsersRosen M, Bridge T, O'Malley S, Pearsall H, Martini B, O'Connor P, Brett‐Smith H, Thomas H, Van Dyck C, Woods S, Kosten T. Peptide T Treatment of Cognitive Impairment in HIV‐Positive Intravenous Drug Users American Journal On Addictions 1992, 1: 332-338. DOI: 10.1111/j.1521-0391.1992.tb00359.x.
  • Peptide T Treatment of Cognitive Impairment in HIV-Positive Intravenous Drug UsersRosen M, Bridge T, O'Malley S, Pearsall H, Martini B, O'Connor P, Brett-Smith H, Thomas H, van Dyck C, Woods S, Kosten T. Peptide T Treatment of Cognitive Impairment in HIV-Positive Intravenous Drug Users American Journal On Addictions 1992, 1: 332-338. DOI: 10.3109/10550499208993153.

Clinical Trials